Depleted dopamine in gastric cancer tissues: Dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis

Clinical Cancer Research

Volumn 10, Issue 13, 2004, Pages 4349-4356

  Chakroborty, Debanjan ^a   Sarkar, Chandrani ^a   Mitra, Rita Basu ^c   Banerjee, Samir ^a   Dasgupta, Partha Sarathi ^a   Basu, Sujit ^a,b  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b MAYO GRADUATE SCHOOL   (United States)

^c INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; DOPAMINE; DOPAMINE 2 RECEPTOR; METHYLNITRONITROSOGUANIDINE; TYROSINE 3 MONOOXYGENASE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DOPAMINE METABOLISM; DOSE RESPONSE; DRUG INHIBITION; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RAT; STOMACH CANCER; STOMACH FUNCTION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ADULT; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARDIOTONIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE PROGRESSION; DOPAMINE; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; METHYLNITRONITROSOGUANIDINE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NEUROTRANSMITTER AGENTS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; STOMACH NEOPLASMS; TYROSINE 3-MONOOXYGENASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 3042734848     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0059     Document Type: Article

References (35)

1. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev 1998;78:189-225.
2. Sźabó S. Dopamine disorder in duodenal ulceration. Lancet 1979;2: 880-2.
3. Eisenhofer G, Åneman A, Friberg P, et al. Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab 1997;82:3864-71.
4. Mezey É, Eisenhofer G, Hansson S, Hunyady B, Hoffman BJ. Dopamine produced by the stomach may act as a paracrine/autocrine hormone in the rat. Neuroendocrinology 1998;67:336-48.
5. Hunyady B, Hoffman BJ, Eisenhofer G, Hansson SR, Mezey E. Dopaminergic characteristics of isolated parietal cells from rats. J Physiol Paris 1997;91:247-56.
6. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:795-803.
7. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature (Lond.) 2000;407:249-57.
8. Jung YD, Mansfield PF, Akagi M, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002;38:1133-40.
9. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80.
10. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-64.
11. Kaise M, Echizen U, Umeda N, Ishizaki T. Catecholamine concentrations in biopsied gastroduodenal tissue specimens of patients with duodenal ulcer. Dig Dis Sci 1993;38:1866-73.
12. Magro F, Vieira-Coelho MA, Fraga S, et al. Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig Dis Sci 2002;47:216-24.
13. Basu S, Nagy JA, Pal S, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001;7:569-74.
14. Sugimura T, Fujimura S. Tumour production in glandular stomach of rat by N-methyl-N′-nitro-N-nitrosoguanidine. Nature (Lond.) 1967; 216:943-4.
15. Keyes KA, Mann L, Cox K, et al. Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology. Cancer Chemother Pharmacol 2003;51:321-7.
16. Yamane T, Takahashi T, Kuwata K, et al. Inhibition of N-methyl-N′-nitro-N-nitrosoguanidine-induced carcinogenesis by (-)-epigallocatechin gallate in the rat glandular stomach. Cancer Res 1995;55:2081-4.
17. Xiao H-B, Cao W-X, Yin H-R, Lin Y-Z, Ye S-H. Influence of L-methionine-deprived total parenteral nutrition with 5-fluorouracil on gastric cancer and host metabolism. World J Gastroenterol 2001;5:698-701.
18. Szepeshazi K, Schally AV, Nagy A, Wagner BW, Bajo AM, Halmos G. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas Cancer (Phila.) 2003;98:1401-10.
19. Man S, Bocci G, Francia G, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731-5.
20. Zaroslinski JF, Possley LH, Schwartz RA, Moris RN, Carone FA, Browne RK. The pharmacology and subacute toxicology of dopamine. Proc R Soc Med 1977;70:2-6.
21. Eldrup E, Ritcher EA. DOPA, dopamine, and DOPAC concentrations in the rat gastrointestinal tract decrease during fasting. Am J Physiol Endocrinol Metab 2000;279:E815-22.
22. Panigrahy D, Singer S, Shen LQ, et al. PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Investig 2002;110:923-32.
23. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Investig 2003;111:1287-95.
24. Joseph IBJK, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997;3:2507-11.
25. Häggström S, Bergh A, Damber J-K. Vascular endothelial growth factor content in content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma. Prostate 2000;45:42-50.
26. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59:5209-18.
27. Ushijima T, Yamamoto M, Suzui M, et al. Chromosomal mapping of genes controlling development, histological grade, depth of invasion, and size of rat stomach carcinomas. Cancer Res 2000;60:1092-6.
28. Ma L, Wallace JL. Endothelial nitric oxide synthase modulates gastric ulcer healing in rats. Am J Physiol Gastrointest Liver Physiol 2000;279:G341-6.
29. Basu S, Dasgupta PS. Role of dopamine in malignant tumor growth. Endocrine 2000;12:237-41.
30. Iishi H, Baba M, Tatsuta M, Okuda S, Taniguchi H. Enhancement of dopaminergic agonist bromocriptine of gastric carcinogenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine in Wistar rats. Br J Cancer 1992;65:351-4.
31. Tatsuta M, Iishi H, Baba M, Nakaizumi A, Uehara H, Taniguchi H. Enhancement by suipiride of the inhibitory effects of cysteamine on gastric carcinogenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer 1991;47:54-9.
32. Tatsuta M, Iishi H, Baba M, et al. Attenuating effect of bromocriptine on cysteamine anticarcinogenesis of stomach cancers induced by N-methyl-N′-nitro-N-nitrosoguanidine. Cancer Res 1990;50:5308-11.
33. Shibata MA, Hirose M, Yamada M, Tatematsu M, Uwagawa S, Ito N. Epithelial cell proliferation in rat forestomach and glandular stomach mucosa induced by catechol and analogous dihydroxybenzenes. Carcinogenesis (Lond.) 1990;11:997-1000.
34. Kimura K. Gastritis and gastric cancer. Asia. Gastroenterol Clin N Am 2000;29:609-21.
35. Katzung BG, editor. Basic and clinical pharmacology. Stamford, CT: Appleton and Lange; 2004.